Suppr超能文献

联合术前癌胚抗原(CEA)、糖类抗原19-9(CA 19-9)和糖类抗原72-4(72-4)浓度预测胃癌根治性切除术后患者的预后

Combined preoperative concentrations of CEA, CA 19-9, and 72-4 for predicting outcomes in patients with gastric cancer after curative resection.

作者信息

Liu Xuechao, Qiu Haibo, Liu Jianjun, Chen Shangxiang, Xu Dazhi, Li Wei, Zhan Youqing, Li Yuanfang, Chen Yingbo, Zhou Zhiwei, Sun Xiaowei

机构信息

Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.

Department of Gastric and Pancreatic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.

出版信息

Oncotarget. 2016 Jun 7;7(23):35446-53. doi: 10.18632/oncotarget.9060.

Abstract

In many cancers, prognostic factors are useful for identifying high-risk patients and in individualizing treatment. We sought to determine whether a combination of tumor markers (CTM) would improve prognostic accuracy in patients with gastric cancer (GC). The CTM score, which is derived from serum concentrations of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), and carbohydrate antigen 72-4 (CA 72-4), was tested retrospectively in 1134 patients with GC undergoing curative resection between October 2000 and December 2012. The CTM score was 2 for patients with two or three elevated markers, 1 for those with one elevated marker, and 0 for those no elevated markers. Overall survival (OS) in patients with CTM scores 0, 1, and 2 was 61.8%, 31.4%, and 15.1%, respectively (P<.001). The CTM score independently predicted OS on multivariate analysis (HR, 1.95; 95% CI, 1.73 to 2.21; P<.001). Moreover, the area under the receiver operating characteristics curve of the CTM score (0.67; 95% CI, 0.64 to 0.70) was higher than the values of any individual marker (0.63, 0.57, 0.57; P<.001 for all comparisons). The CTM score independently predicted postoperative survival in GC, and it may have better clinical utility than individual tumor markers for identifying high-risk patients with GC.

摘要

在许多癌症中,预后因素有助于识别高危患者并实现个体化治疗。我们试图确定肿瘤标志物组合(CTM)是否能提高胃癌(GC)患者的预后准确性。CTM评分源自癌胚抗原(CEA)、糖类抗原19-9(CA 19-9)和糖类抗原72-4(CA 72-4)的血清浓度,对2000年10月至2012年12月期间接受根治性切除术的1134例GC患者进行了回顾性测试。有两个或三个标志物升高的患者CTM评分为2,有一个标志物升高的患者评分为1,无标志物升高的患者评分为0。CTM评分为0、1和2的患者的总生存期(OS)分别为61.8%、31.4%和15.1%(P<0.001)。多因素分析显示CTM评分可独立预测OS(HR,1.95;95%CI,1.73至2.21;P<0.001)。此外,CTM评分的受试者工作特征曲线下面积(0.67;95%CI,0.64至0.70)高于任何单个标志物的值(0.63、0.57、0.57;所有比较P<0.001)。CTM评分可独立预测GC患者的术后生存期,在识别GC高危患者方面可能比单个肿瘤标志物具有更好的临床实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1894/5085242/d835cdb18a4f/oncotarget-07-35446-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验